Eli Lilly and Company

LLY

NYSEBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 15, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
Intramuscular Glucagon	Phase 3	Diabetes Mellitus, Type 1	-
LY900014	Phase 3	Type 1 Diabetes Mellitus	-
Gemcitabine	Phase 3	Non-Small Cell Lung Cancer	-
Ixekizumab Auto-Injector	Phase 3	Plaque Psoriasis	-
pemetrexed	Phase 3	Non-Small Cell Lung Cancer	-
Erlotinib	Phase 3	Non Small Cell Lung Cancer	-
GEMZAR	Phase 3	Pancreatic Neoplasms	-
Dulaglutide	Phase 3	Type 2 Diabetes Mellitus	-
LY2605541	Phase 3	Type 1 Diabetes Mellitus	-
Baricitinib	Phase 3	Systemic Juvenile Idiopathic Arthritis	-
Galcanezumab	Phase 3	Chronic Migraine	-
Ixekizumab	Phase 3	Psoriasis	-
Tirzepatide	Phase 3	Overweight	-
Remternetug (IV)	Phase 3	Alzheimer's Disease	-
LY353381	Phase 3	Breast Neoplasms	-
Insulin Peglispro	Phase 3	Type 2 Diabetes Mellitus	-
olanzapine	Phase 3	Bipolar Disorder I or II	-
teriparatide	Phase 3	Osteoporosis, Postmenopausal	-
Insulin Lispro	Phase 3	Type 2 Diabetes Mellitus	-
venlafaxine	Phase 3	Anxiety Disorders	-
Capecitabine	Phase 3	Metastatic Gastric Adenocarcinoma	-
Tadalafil	Phase 3	Benign Prostatic Hyperplasia	-
Fulvestrant	Phase 3	Breast Neoplasms	-
Methylphenidate	Phase 3	Attention Deficit Hyperactivity Disorder	-
Glargine	Phase 3	Diabetes Mellitus, Type 1	-
lithium	Phase 3	Manic or Mixed Episode Associated With Bipolar I Disorder	-
Insulin Lispro Protamine Suspension	Phase 3	Diabetes Mellitus, Type 2	-
Somatropin	Phase 3	Growth Hormone Deficiency	-
Nasal Glucagon	Phase 3	Hypoglycemia	-
Lasmiditan	Phase 3	Migraine	-
Insulin Glargine	Phase 3	Diabetes Mellitus, Type 2	-
Olanzapine Hydrochloride	Phase 3	Bipolar Disorder	-
Duloxetine hydrochloride	Phase 3	Diabetic Neuropathy, Painful	-
Tirzepatide Dose 1	Phase 3	Type2 Diabetes	-
Retatrutide	Phase 3	Obesity	-
Ultra-Rapid Lispro	Phase 3	Type 1 Diabetes Mellitus	-
Atomoxetine Hydrochloride	Phase 3	Attention Deficit Hyperactivity Disorder	-
Duloxetine	Phase 3	Urinary Stress Incontinence	-
LY2216684	Phase 3	Major Depressive Disorder	-
Insulin Efsitora Alfa	Phase 3	Type 2 Diabetes	-
LY3819253	Phase 3	COVID-19	-
cetuximab	Phase 2	Colorectal Neoplasms	-
Abemaciclib	Phase 2	Breast Cancer	-
Raloxifene	Phase 2	Vasomotor Symptoms	-
Clopidogrel	Phase 2	Acute Coronary Syndrome	-
Erbitux (Cetuximab)	Phase 2	Colorectal Neoplasms	-
Ramucirumab	Phase 2	Gastric Adenocarcinoma	-
Placebo for Prasugrel	Phase 2	Coronary Artery Disease	-
Prasugrel	Phase 2	Sickle Cell Anemia	-
Galunisertib	Phase 2	Glioblastoma	-
LY3305677	Phase 2	Obesity	-
Prexasertib	Phase 2	Ovarian Cancer	-
LY2140023	Phase 2	Schizophrenia	-
LY3209590	Phase 2	Type 2 Diabetes Mellitus	-
Mirikizumab	Phase 2	Ulcerative Colitis	-
LY2603618	Phase 2	Non Small Cell Lung Cancer	-
Cyclophosphamide	Phase 2	Desmoplastic Small Round Cell Tumor	-
LY2439821	Phase 2	Rheumatoid Arthritis	-
enzastaurin	Phase 2	Non-Small Cell Lung Cancer	-
Paclitaxel	Phase 2	Non Small Cell Lung Cancer	-
LY2127399	Phase 2	Arthritis, Rheumatoid	-
Necitumumab	Phase 2	Solid Tumors	-
cisplatin	Phase 2	Non-Small Cell Lung Cancer	-
IMC-1121B (ramucirumab)	Phase 2	Carcinoma, Non-Small-Cell Lung	-
Emibetuzumab	Phase 2	Carcinoma, Non-Small-Cell Lung	-
Testosterone Solution 2%	Phase 2	Ejaculatory Dysfunction	-
STX-478	Phase 2	Breast Cancer	-
Nivolumab	Phase 2	Solid Tumor	-
Placebo	Phase 2	Acute Pain	-
LY2452473	Phase 2	Erectile Dysfunction	-
LY3016859	Phase 2	Osteoarthritis	-
Zagotenemab	Phase 2	Alzheimer Disease (AD)	-
MORF-057	Phase 2	Inflammatory Bowel Diseases	-
Cetuximab + platinum + gemcitabine	Phase 2	Non-Small-Cell Lung Carcinoma	-

Catalyst Timeline

5 upcoming, 0 past

⭐Phase 3Next

Ixekizumab Phase 3 Results Expected

December 2025~Ixekizumab

Primary completion for Ixekizumab trial (NCT06588283) in Psoriasis

Source

⭐Phase 3

Placebo Phase 3 Results Expected

April 2026~Placebo

Primary completion for Placebo trial (NCT05882045) in Obesity

Source

⭐Phase 3

Retatrutide Phase 3 Results Expected

April 2026~Retatrutide

Primary completion for Retatrutide trial (NCT05882045) in Obesity

Source

⭐Phase 3

Baricitinib Phase 3 Results Expected

April 2026~Baricitinib

Primary completion for Baricitinib trial (NCT04088396) in Systemic Juvenile Idiopathic Arthritis

Source

Phase 2

LY3305677 Phase 2 Results Expected

June 2026~LY3305677

Primary completion for LY3305677 trial (NCT06143956) in Obesity

Source

Regulatory Approvals

LLY News

Eli Lilly and Company

LLY

NYSEBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 15, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
Intramuscular Glucagon	Phase 3	Diabetes Mellitus, Type 1	-
LY900014	Phase 3	Type 1 Diabetes Mellitus	-
Gemcitabine	Phase 3	Non-Small Cell Lung Cancer	-
Ixekizumab Auto-Injector	Phase 3	Plaque Psoriasis	-
pemetrexed	Phase 3	Non-Small Cell Lung Cancer	-
Erlotinib	Phase 3	Non Small Cell Lung Cancer	-
GEMZAR	Phase 3	Pancreatic Neoplasms	-
Dulaglutide	Phase 3	Type 2 Diabetes Mellitus	-
LY2605541	Phase 3	Type 1 Diabetes Mellitus	-
Baricitinib	Phase 3	Systemic Juvenile Idiopathic Arthritis	-
Galcanezumab	Phase 3	Chronic Migraine	-
Ixekizumab	Phase 3	Psoriasis	-
Tirzepatide	Phase 3	Overweight	-
Remternetug (IV)	Phase 3	Alzheimer's Disease	-
LY353381	Phase 3	Breast Neoplasms	-
Insulin Peglispro	Phase 3	Type 2 Diabetes Mellitus	-
olanzapine	Phase 3	Bipolar Disorder I or II	-
teriparatide	Phase 3	Osteoporosis, Postmenopausal	-
Insulin Lispro	Phase 3	Type 2 Diabetes Mellitus	-
venlafaxine	Phase 3	Anxiety Disorders	-
Capecitabine	Phase 3	Metastatic Gastric Adenocarcinoma	-
Tadalafil	Phase 3	Benign Prostatic Hyperplasia	-
Fulvestrant	Phase 3	Breast Neoplasms	-
Methylphenidate	Phase 3	Attention Deficit Hyperactivity Disorder	-
Glargine	Phase 3	Diabetes Mellitus, Type 1	-
lithium	Phase 3	Manic or Mixed Episode Associated With Bipolar I Disorder	-
Insulin Lispro Protamine Suspension	Phase 3	Diabetes Mellitus, Type 2	-
Somatropin	Phase 3	Growth Hormone Deficiency	-
Nasal Glucagon	Phase 3	Hypoglycemia	-
Lasmiditan	Phase 3	Migraine	-
Insulin Glargine	Phase 3	Diabetes Mellitus, Type 2	-
Olanzapine Hydrochloride	Phase 3	Bipolar Disorder	-
Duloxetine hydrochloride	Phase 3	Diabetic Neuropathy, Painful	-
Tirzepatide Dose 1	Phase 3	Type2 Diabetes	-
Retatrutide	Phase 3	Obesity	-
Ultra-Rapid Lispro	Phase 3	Type 1 Diabetes Mellitus	-
Atomoxetine Hydrochloride	Phase 3	Attention Deficit Hyperactivity Disorder	-
Duloxetine	Phase 3	Urinary Stress Incontinence	-
LY2216684	Phase 3	Major Depressive Disorder	-
Insulin Efsitora Alfa	Phase 3	Type 2 Diabetes	-
LY3819253	Phase 3	COVID-19	-
cetuximab	Phase 2	Colorectal Neoplasms	-
Abemaciclib	Phase 2	Breast Cancer	-
Raloxifene	Phase 2	Vasomotor Symptoms	-
Clopidogrel	Phase 2	Acute Coronary Syndrome	-
Erbitux (Cetuximab)	Phase 2	Colorectal Neoplasms	-
Ramucirumab	Phase 2	Gastric Adenocarcinoma	-
Placebo for Prasugrel	Phase 2	Coronary Artery Disease	-
Prasugrel	Phase 2	Sickle Cell Anemia	-
Galunisertib	Phase 2	Glioblastoma	-
LY3305677	Phase 2	Obesity	-
Prexasertib	Phase 2	Ovarian Cancer	-
LY2140023	Phase 2	Schizophrenia	-
LY3209590	Phase 2	Type 2 Diabetes Mellitus	-
Mirikizumab	Phase 2	Ulcerative Colitis	-
LY2603618	Phase 2	Non Small Cell Lung Cancer	-
Cyclophosphamide	Phase 2	Desmoplastic Small Round Cell Tumor	-
LY2439821	Phase 2	Rheumatoid Arthritis	-
enzastaurin	Phase 2	Non-Small Cell Lung Cancer	-
Paclitaxel	Phase 2	Non Small Cell Lung Cancer	-
LY2127399	Phase 2	Arthritis, Rheumatoid	-
Necitumumab	Phase 2	Solid Tumors	-
cisplatin	Phase 2	Non-Small Cell Lung Cancer	-
IMC-1121B (ramucirumab)	Phase 2	Carcinoma, Non-Small-Cell Lung	-
Emibetuzumab	Phase 2	Carcinoma, Non-Small-Cell Lung	-
Testosterone Solution 2%	Phase 2	Ejaculatory Dysfunction	-
STX-478	Phase 2	Breast Cancer	-
Nivolumab	Phase 2	Solid Tumor	-
Placebo	Phase 2	Acute Pain	-
LY2452473	Phase 2	Erectile Dysfunction	-
LY3016859	Phase 2	Osteoarthritis	-
Zagotenemab	Phase 2	Alzheimer Disease (AD)	-
MORF-057	Phase 2	Inflammatory Bowel Diseases	-
Cetuximab + platinum + gemcitabine	Phase 2	Non-Small-Cell Lung Carcinoma	-